MA28041A1 - Molecules de liaison therapeutiques - Google Patents
Molecules de liaison therapeutiquesInfo
- Publication number
- MA28041A1 MA28041A1 MA28875A MA28875A MA28041A1 MA 28041 A1 MA28041 A1 MA 28041A1 MA 28875 A MA28875 A MA 28875A MA 28875 A MA28875 A MA 28875A MA 28041 A1 MA28041 A1 MA 28041A1
- Authority
- MA
- Morocco
- Prior art keywords
- ser
- asn
- amino acid
- tyr
- thr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
L'invention concerne une molécule comprenant au moins un site de liaison antigène, comprenant en séquences des régions hypervariables CDR1, CDR2 et CDR3, ladite CDR1 présentant une séquence d'aminoacides Asn-Tyr-Ile-IIe-His (NYIIH), ladite CDR2 présentant une séquence d'aminoacide Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe -Lys-GIy (YFNPYNHGTKYNEKFKG) et ladite CDR3 présentant une séquence d'aminoacide Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT) ; par exemple comprenant, de plus, en séquences les régions hypervariables CDR1', CDR2' et CDR3', CDR1' présentant la séquence d'aminoacide Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-IIe-Gln (RASQNIGTSIQ) ; CDR2' présentant la séquence d'aminoacide Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) et CDR31 présentant la séquence d'aminoacide Gln-GIn-Ser-Asn-Thr-Trp- Pro-Phe-Thr (QQSNTWPFT), par exemple un anticorps chimère ou humanisé, utilisé en tant que produit pharmaceutique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/666,332 US20050069538A1 (en) | 2003-09-18 | 2003-09-18 | Therapeutic binding molecules |
GB0414309A GB0414309D0 (en) | 2004-06-25 | 2004-06-25 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28041A1 true MA28041A1 (fr) | 2006-07-03 |
Family
ID=34315457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28875A MA28041A1 (fr) | 2003-09-18 | 2006-03-14 | Molecules de liaison therapeutiques |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP1664122B1 (fr) |
JP (1) | JP4762142B2 (fr) |
KR (1) | KR20060079232A (fr) |
AR (2) | AR045765A1 (fr) |
AT (1) | ATE461219T1 (fr) |
AU (1) | AU2004272289B2 (fr) |
BR (1) | BRPI0414515A (fr) |
CA (1) | CA2537217A1 (fr) |
CY (1) | CY1110033T1 (fr) |
DE (1) | DE602004026081D1 (fr) |
DK (1) | DK1664122T3 (fr) |
EC (1) | ECSP066432A (fr) |
ES (1) | ES2341341T3 (fr) |
HK (1) | HK1091844A1 (fr) |
HR (1) | HRP20100334T1 (fr) |
IL (1) | IL173820A0 (fr) |
IS (1) | IS8397A (fr) |
MA (1) | MA28041A1 (fr) |
MY (1) | MY143963A (fr) |
NO (1) | NO20061681L (fr) |
NZ (1) | NZ545605A (fr) |
PE (1) | PE20060019A1 (fr) |
PL (1) | PL1664122T3 (fr) |
PT (1) | PT1664122E (fr) |
RU (1) | RU2386639C2 (fr) |
SI (1) | SI1664122T1 (fr) |
TN (1) | TNSN06087A1 (fr) |
TW (1) | TW200521231A (fr) |
WO (1) | WO2005026210A2 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2502631A1 (fr) | 2011-03-22 | 2012-09-26 | Medizinische Hochschule Hannover | Immunosuppresseur et son utilisation |
GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
CN105886609B (zh) * | 2015-02-17 | 2020-02-21 | 陈沛隆 | 药物不良反应风险评估方法及其装置 |
CA2982115A1 (fr) | 2015-04-06 | 2016-10-13 | President And Fellows Of Harvard College | Compositions et procedes s'appliquant au conditionnement non myeloablatif |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
JP2019522050A (ja) * | 2016-06-17 | 2019-08-08 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | 細胞の枯渇のための組成物および方法 |
JP2020522254A (ja) | 2017-05-31 | 2020-07-30 | エルスター セラピューティクス, インコーポレイテッド | 骨髄増殖性白血病(mpl)タンパク質に結合する多特異性分子およびその使用 |
WO2022079199A1 (fr) | 2020-10-15 | 2022-04-21 | UCB Biopharma SRL | Molécules de liaison multimérisant cd45 |
IL303270A (en) | 2020-12-21 | 2023-07-01 | Allogene Therapeutics Inc | The CD45–GATE vehicle activates a protease |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6106834A (en) * | 1993-06-02 | 2000-08-22 | Research Corporation Technologies, Inc. | Use of anti-CD45 leukocyte antigen antibodies for immunomodulation |
GB0103389D0 (en) * | 2001-02-12 | 2001-03-28 | Novartis Ag | Organic compounds |
-
2004
- 2004-09-17 CA CA002537217A patent/CA2537217A1/fr not_active Abandoned
- 2004-09-17 WO PCT/EP2004/010471 patent/WO2005026210A2/fr active Application Filing
- 2004-09-17 BR BRPI0414515-1A patent/BRPI0414515A/pt not_active Application Discontinuation
- 2004-09-17 RU RU2006112598/13A patent/RU2386639C2/ru not_active IP Right Cessation
- 2004-09-17 TW TW093128255A patent/TW200521231A/zh unknown
- 2004-09-17 AU AU2004272289A patent/AU2004272289B2/en not_active Ceased
- 2004-09-17 KR KR1020067005352A patent/KR20060079232A/ko not_active Application Discontinuation
- 2004-09-17 ES ES04765363T patent/ES2341341T3/es active Active
- 2004-09-17 PT PT04765363T patent/PT1664122E/pt unknown
- 2004-09-17 NZ NZ545605A patent/NZ545605A/en not_active IP Right Cessation
- 2004-09-17 PL PL04765363T patent/PL1664122T3/pl unknown
- 2004-09-17 EP EP04765363A patent/EP1664122B1/fr active Active
- 2004-09-17 JP JP2006526599A patent/JP4762142B2/ja not_active Expired - Fee Related
- 2004-09-17 AR ARP040103362A patent/AR045765A1/es active IP Right Grant
- 2004-09-17 MY MYPI20043795A patent/MY143963A/en unknown
- 2004-09-17 AT AT04765363T patent/ATE461219T1/de active
- 2004-09-17 DE DE602004026081T patent/DE602004026081D1/de active Active
- 2004-09-17 SI SI200431411T patent/SI1664122T1/sl unknown
- 2004-09-17 PE PE2004000909A patent/PE20060019A1/es not_active Application Discontinuation
- 2004-09-17 DK DK04765363.9T patent/DK1664122T3/da active
-
2006
- 2006-02-20 IL IL173820A patent/IL173820A0/en not_active IP Right Cessation
- 2006-03-14 MA MA28875A patent/MA28041A1/fr unknown
- 2006-03-17 EC EC2006006432A patent/ECSP066432A/es unknown
- 2006-03-17 TN TNP2006000087A patent/TNSN06087A1/en unknown
- 2006-04-03 IS IS8397A patent/IS8397A/is unknown
- 2006-04-12 NO NO20061681A patent/NO20061681L/no not_active Application Discontinuation
- 2006-11-09 HK HK06112334.4A patent/HK1091844A1/xx unknown
-
2010
- 2010-05-14 CY CY20101100424T patent/CY1110033T1/el unknown
- 2010-06-10 HR HR20100334T patent/HRP20100334T1/hr unknown
- 2010-12-14 AR ARP100104624A patent/AR079458A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28041A1 (fr) | Molecules de liaison therapeutiques | |
BR0207151A (pt) | Moléculas de aglutinação terapêuticas | |
AR046379A1 (es) | Una molecula de enlace de mcp-1 humana, un proceso para dicha produccion, construcciones de adn, un vector de expresion, composiciones farmaceuticas y el uso de dicha molecula de enlace de mcp-1 para la preparacion de un medicamento | |
RS54088B1 (en) | B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES | |
WO2004066932A3 (fr) | Composition permettant de traiter des maladies dues a la demyelinisation et a la paralysie par administration d'agents de remyelinisation | |
RS51468B (en) | COMPLETE HUMAN ANTIBODIES FOR HUMANS 4-1BB (CD137) | |
ATE454124T1 (de) | Rekombinante anti-cd30-antikörper und deren verwendungen | |
IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
WO1998057994A3 (fr) | Anticorps opsoniques, monoclonaux protecteurs, et chimeres specifiques a l'acide lipoteichoique des bacteries gram positif | |
MA28982B1 (fr) | Anticorps antagonistes de il-17 | |
CO5280086A1 (es) | Molecula de enlace de cd154, construccion de adn, vector de expresion, composcion y combinacion farmaceutica | |
AR035581A1 (es) | Anticuerpos para il-1beta humana | |
WO2006083964A3 (fr) | Molecules de fusion modifiees pour le traitement de maladies allergiques | |
ECSP055849A (es) | Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico | |
Delehanty et al. | Identification of Important Residues in Metal− Chelate Recognition by Monoclonal Antibodies | |
BR0210648A (pt) | Variante de uma molécula imunointerativa, anticorpo monoclonal, forma disimunizada de anticorpo monoclonal 3b6, método para a geração de um anticorpo monoclonal desimunizado, molécula de anticorpo desimunizada, anticorpo desimunizado, anticorpo monoclonal de murino variante 3b6 desimunizado, variante de um anticorpo monoclonal de murino 3b6 desimunizado para uso em humanos, método para a detecção de um coágulo sanguìneo em um paciente humano, método para a detecção de um coágulo sanguìneo ou de um seu fragmento de ligação a antìgeno, método para a facilitação da dissolução ou da remoção de um coágulo sanguìneo em um humano, uso de um anticorpo monoclonal derivado de murino variante, e, conjugado | |
BRPI0409736A (pt) | anticorpos monoclonais, variantes de polipeptìdeo stop-1, molécula de ácido nucléico, vetor, célula hospedeira, composições, métodos relativos e artigos industrializados | |
BR0109549A (pt) | Utilização de moléculas que se ligam a cd25 no tratamento de doenças inflamatórias do trato gastrointestinal | |
Wilbur et al. | Streptavidin in antibody pretargeting. Comparison of a recombinant streptavidin with two streptavidin mutant proteins and two commercially available streptavidin proteins | |
IS6908A (is) | Smíðuð mannleg peptíð og lyfjafræðilegar samsetningar sem innihalda þau til meðhöndlunar á rauðum úlfum | |
CY1107785T1 (el) | Χρηση του βασιλιξιμαμπ στη θεραπεια της ρευματοειδους αρθριτιδας ´η νοσων του δερματος | |
WO2004100882A3 (fr) | Inhibition de medicament se liant a la serumalbumine | |
Onda et al. | Mutants of immunotoxin anti-Tac (dsFv)-PE38 with variable number of lysine residues as candidates for site-specific chemical modification. 1. Properties of mutant molecules | |
TH62172A (th) | โมเลกุลยึดประสานที่ใช้บำบัดรักษา | |
WO2022212654A3 (fr) | Anticorps monoclonaux à réaction croisée contre les coronavirus |